Data recently presented at the Society for Neuro-Oncology (SNO) 27th Annual Meeting
Preliminary results showcase updated patient population profile and safety
Continued progress toward planned interim analysis when 30-50% of subjects are evaluable at 6 months after enrollment on the study, expected mid-year 2023
https://finance.yahoo.com/news/cns-pharmaceuticals-announces-preliminary-results-140800610.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.